Custom service

Antimicrobial Cyclic Peptide Development

Develop cyclic antimicrobial peptides with stability and selectivity testing

Turnaround: 6–10 weeksTypical scale: 1 – 200 mg cyclic peptideChemistry options: cyclotin and AMP motif engineering; selectivity (hemolysis) profiling; protease-stability screening

Antimicrobial Cyclic Peptide Development supports programmes that develop cyclic antimicrobial peptides with stability and selectivity testing. In a typical engagement we plan the cyclotin and AMP motif engineering route first, confirm compatibility with selectivity (hemolysis) profiling, and release lead cyclic AMP with activity and selectivity report on a 6–10 weeks schedule.

Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep cyclotin and AMP motif engineering as the primary option and hold selectivity (hemolysis) profiling in reserve, so that scale-up never depends on an unproven step.

Gram-positive and Gram-negative spectrum expansion

Anti-biofilm peptide development

Clinical candidate development past lead stage

Cycles whose ring size is known to be geometrically uncloseable

Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.

Service Highlights

  • Cyclotin and AMP motif engineering as the default route, with selectivity (hemolysis) profiling held as a proven fallback
  • Protease-stability screening worked into the design where the application requires it
  • Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
  • Analytical confirmation of every intermediate before the final release
  • Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
  • Lead cyclic AMP with activity and selectivity report delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Precursor design

    Linear precursor, cyclization sites and protecting strategy are designed around the Antimicrobial Cyclic Peptide Development ring size.

  2. Linear assembly

    The precursor chain is assembled with Fmoc chemistry and cyclotin and AMP motif engineering where relevant.

  3. Cyclization

    Ring closure is executed by selectivity (hemolysis) profiling under screened dilution and activation conditions.

  4. Isomer separation

    RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.

  5. Characterization

    Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.

  6. Release

    Lead cyclic AMP with activity and selectivity report is documented and released after QC sign-off.

Specifications & timeline

Turnaround
6–10 weeks
Typical scale
1 – 200 mg cyclic peptide
Chemistry options
cyclotin and AMP motif engineering; selectivity (hemolysis) profiling; protease-stability screening
Deliverable
Lead cyclic AMP with activity and selectivity report
QC package
HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
Shipping
Ambient with desiccant; blue ice for sensitive motifs

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.